Oncolytics Biotech Inc(ONCY) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.27 | Insider Own | 1.55% | Shs Outstand | 124.6M | Perf Week | -7.28% |
| Market Cap | 0.06B | Forward P/E | - | EPS next Y | 22.72% | Insider Trans | - | Shs Float | 98.8M | Perf Month | -30.27% |
| Enterprise Value | 0.06B | PEG | - | EPS next Q | -0.05 | Inst Own | 11.55% | Short Float | 9.13% | Perf Quarter | -38.49% |
| Income | -0.03B | P/S | - | EPS this Y | -18.2% | Inst Trans | 0.54% | Short Ratio | 8.82 | Perf Half Y | -48.66% |
| Sales | 0.00B | P/B | - | EPS next 5Y | 4% | ROA | -277.89% | Short Interest | 9.03M | Perf YTD | -47.11% |
| Book/sh | -0.05 | P/C | 14.31 | EPS past 3/5Y | 3% 6.32% | ROE | -11838.99% | 52W High | -64.98% ($1.32) | Perf Year | -61.79% |
| Cash/sh | 0.03 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 4.73% ($0.44) | Perf 3Y | -69.98% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 2.05% | Gross Margin | - | Volatility(W/M) | 6.39% 9.95% | Perf 5Y | -77.23% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.05 | Perf 10Y | -79.07% |
| Dividend Ex-Date | - | Quick Ratio | 1.35 | EPS Q/Q | -35.86% | Profit Margin | - | RSI (14) | 27.73 | Recom | 1.4 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.35 | Sales Q/Q | - | SMA20 | -14.58% ($0.54) | Beta | 1.22 | Target Price | $4.41 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/12 | SMA50 | -33.09% ($0.69) | Rel Volume | 0.84 | Prev Close | $0.47 |
| Employees | 29 | LT Debt/Eq | - | EPS/Sales Surpr. | -46.79% - | SMA200 | -46.99% ($0.87) | Avg Volume(3M) | 1.02M | Price | $0.46 |
| IPO | 2001/10/5 | Option/Short | No/Yes | Trades | 1832 | Volume | 859,334 | Change | -2.3% |
🧬 Oncolytics Biotech (ONCY) is a clinical-stage biotech company developing virus-based immuno-oncology therapies. Its lead candidate, pelareorep, works by selectively infecting and destroying tumor cells while triggering an immune response, and is being evaluated in clinical trials across multiple solid tumor indications, including breast cancer and pancreatic cancer.
Over the past 1 year, on the lower side
65% below its 1-year high.
Traded about as much as usual. That is 84% of its average volume.
ONCY has weak earning power
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -18.2% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -77.2%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 11.6%.
Tap to view numbers
It ranks #399 of 594 in the industry
Based on market cap of $59M.
GOSS#397 Gossamer Bio Inc $60M PER - 
VRCA#398 Verrica Pharmaceuticals Inc $60M PER - ONCY#399 Oncolytics Biotech Inc $59M PER - 
OSTX#400 OS Therapies Inc $58M PER - 
HRTX#401 Heron Therapeutics Inc $57M PER - 
FAQ
What kind of company is ONCY?
ONCY belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ONCY?
The market cap of ONCY is approximately $59M, ranking 4,753 within its sector.
What is the 52-week high and low for ONCY?
ONCY has recorded a 52-week high of $1.32 and a low of $0.44.
